Filter Search


Healthcare and Medical


Location Summary Deadline
Germany Completion Of A Non -exclusive Discount Agreement According To Section 130a (8) Sgb V On The Active Ingredient Certolizumab Pegol, Atc L04ab05 For The Period 01.08.2025 - 31.07.2027 2025-12-13
Germany Open House Pharmaceutical Department Treaties Erythropoietin Zeta, Atc B03ax01 2025-12-13
Germany Completion Of A Non -exclusive Discount Agreement According To Section 130a (8) Sgb V On The Active Ingredient Tralokinumab, Atc D11ah07 For The Period 01.08.2025 - 31.07.2027 2025-12-13
Germany Open House Medicinal Practice Treaties Tofacitinib, Atc L04af01 2025-12-13
Germany Open House Pharmaceutical Dact Treaties Brinzolamid And Brimonidin, Atc S01ec24 2025-12-13
Germany Completion Of A Non -exclusive Discount Agreement According To Section 130a (8) Sgb V For The Active Ingredient Felbamat, Atc N03ax10 For The Period 01.08.2025 - 31.07.2027 2025-12-13
Germany Open House Pharmaceutical Dact Treaties Brinzolamid And Brimonidin, Atc S01ec24 2025-12-13
Germany Completion Of A Non -exclusive Discount Agreement According To Section 130a (8) Sgb V On The Active Ingredient Ponesimod, Atc L04ae04 For The Period 01.08.2025 - 31.07.2027 2025-12-13
Germany Completion Of A Non -exclusive Discount Agreement According To Section 130a (8) Sgb V For The Active Ingredient Melatonin (exclusively 1mg And 5mg), Atc N05ch01 For The Period 01.08.2025 - 31.2012027 2025-12-13
Germany Completion Not Excl. Pharmaceutical Discount Club. According To § 130a Para. 8 Sgb V In The Way Of An Open House Model To The Active Ingredient Pegintereron Beta1a (atccode According To Who 2025-12-13
Whats app